Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J. Mastrangelo

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Methods and Findings in Experimental and Clinical Pharmacology|September 1, 1987
Elimination of immune suppressor mechanisms in humans by oxazaphosphorinesD Berd, M J Mastrangelo
British Journal of Cancer|December 1, 1981
Differential sensitivity of two murine leukaemia sublines to cytolysis by Corynebacterium parvum-activated macrophagesD Berd, M J Mastrangelo
Cancer Research|June 15, 1987
Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subsetD Berd, M J Mastrangelo
Cancer Research|May 15, 1987
Depletion of suppressor-cytotoxic T-lymphocytes by administration of a murine monoclonal antibodyD Berd, M J Mastrangelo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1995
Combination chemotherapy of metastatic melanomaD Berd, M J Mastrangelo
Seminars in Oncology|February 1, 1989
The pathophysiology and staging of cutaneous malignant melanomaS Schultz, M J Mastrangelo
Cancer Investigation|January 1, 1988
Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamideD Berd, M J Mastrangelo
Cancer Research|March 15, 1988
Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cellsD Berd, M J Mastrangelo
Cancer Chemotherapy Reports|April 1, 1970
Phase I study of a combination of azotomycin (NSC-56654) and 5-fluorouracil (NSC-19893) in malignant diseaseA J Weiss, M J Mastrangelo
Seminars in Oncology|December 1, 1995
Adjuvant therapy for cutaneous melanomaF E Nathan, M J Mastrangelo
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Methods and Findings in Experimental and Clinical Pharmacology|September 1, 1987
Elimination of immune suppressor mechanisms in humans by oxazaphosphorinesD Berd, M J Mastrangelo
British Journal of Cancer|December 1, 1981
Differential sensitivity of two murine leukaemia sublines to cytolysis by Corynebacterium parvum-activated macrophagesD Berd, M J Mastrangelo
Cancer Research|June 15, 1987
Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subsetD Berd, M J Mastrangelo
Cancer Research|May 15, 1987
Depletion of suppressor-cytotoxic T-lymphocytes by administration of a murine monoclonal antibodyD Berd, M J Mastrangelo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1995
Combination chemotherapy of metastatic melanomaD Berd, M J Mastrangelo
Seminars in Oncology|February 1, 1989
The pathophysiology and staging of cutaneous malignant melanomaS Schultz, M J Mastrangelo
Cancer Investigation|January 1, 1988
Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamideD Berd, M J Mastrangelo
Cancer Research|March 15, 1988
Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cellsD Berd, M J Mastrangelo
Cancer Chemotherapy Reports|April 1, 1970
Phase I study of a combination of azotomycin (NSC-56654) and 5-fluorouracil (NSC-19893) in malignant diseaseA J Weiss, M J Mastrangelo
Seminars in Oncology|December 1, 1995
Adjuvant therapy for cutaneous melanomaF E Nathan, M J Mastrangelo
Pageof 12